PFE

PfizerNYSE:PFE Stock Report

Market Cap

US$246.1b

7D

-3.7%

1Y

19.8%

Updated

18 Sep, 2021

Data

Company Financials +
PFE fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance4/6
Financial Health4/6
Dividends5/6

PFE Overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

Pfizer Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pfizer
Historical stock prices
Current Share PriceUS$43.89
52 Week HighUS$33.36
52 Week LowUS$51.86
Beta0.68
1 Month Change-10.06%
3 Month Change13.09%
1 Year Change19.82%
3 Year Change-0.39%
5 Year Change28.11%
Change since IPO1,383.61%

Recent News & Updates

Sep 07

Pfizer's 3CL Protease Inhibitor May Cut The Achilles' Heel Of COVID-19

Novel 3CL protease inhibitor under development. Pivot in vaccination strategy telegraphed in Fox interview. Hole in vaccination strategy creates a greater need for oral antivirals. Competition lurking but underfunded.

Sep 04
Even with Vaccine Success, Pfizer (NYSE:PFE) Returns are Lagging the Broad Market

Even with Vaccine Success, Pfizer (NYSE:PFE) Returns are Lagging the Broad Market

There are but few corners of the Earth that the brand power of Pfizer Inc. (NYSE: PFE) didn't reach in recent times, as a pharmaceutical giant made the best out of one of the more peculiar moments in recent history. This article will examine the latest developments and look at the total shareholder returns stretching back the last 5 years.

Shareholder Returns

PFEUS PharmaceuticalsUS Market
7D-3.7%-2.5%-0.6%
1Y19.8%11.0%33.8%

Return vs Industry: PFE exceeded the US Pharmaceuticals industry which returned 11% over the past year.

Return vs Market: PFE underperformed the US Market which returned 33.8% over the past year.

Price Volatility

Is PFE's price volatile compared to industry and market?
PFE volatility
PFE Beta0.68
Industry Beta0.64
Market Beta1

Stable Share Price: PFE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: PFE's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
184978,500Albert Bourlahttps://www.pfizer.com

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands.

Pfizer Fundamentals Summary

How do Pfizer's earnings and revenue compare to its market cap?
PFE fundamental statistics
Market CapUS$246.08b
Earnings (TTM)US$12.32b
Revenue (TTM)US$55.52b

20.0x

P/E Ratio

4.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PFE income statement (TTM)
RevenueUS$55.52b
Cost of RevenueUS$16.03b
Gross ProfitUS$39.49b
ExpensesUS$27.16b
EarningsUS$12.32b

Last Reported Earnings

Jul 04, 2021

Next Earnings Date

n/a

Earnings per share (EPS)2.21
Gross Margin71.12%
Net Profit Margin22.20%
Debt/Equity Ratio55.8%

How did PFE perform over the long term?

See historical performance and comparison

Dividends

3.6%

Current Dividend Yield

70%

Payout Ratio

Valuation

Is Pfizer undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PFE ($43.89) is trading below our estimate of fair value ($94.3)

Significantly Below Fair Value: PFE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PFE is good value based on its PE Ratio (20x) compared to the US Pharmaceuticals industry average (22.9x).

PE vs Market: PFE is poor value based on its PE Ratio (20x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: PFE's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: PFE is overvalued based on its PB Ratio (3.5x) compared to the US Pharmaceuticals industry average (3.3x).


Future Growth

How is Pfizer forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

-2.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PFE's earnings are forecast to decline over the next 3 years (-2.2% per year).

Earnings vs Market: PFE's earnings are forecast to decline over the next 3 years (-2.2% per year).

High Growth Earnings: PFE's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PFE's revenue is expected to decline over the next 3 years (-9.2% per year).

High Growth Revenue: PFE's revenue is forecast to decline over the next 3 years (-9.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PFE's Return on Equity is forecast to be high in 3 years time (21.2%)


Past Performance

How has Pfizer performed over the past 5 years?

-2.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PFE has high quality earnings.

Growing Profit Margin: PFE's current net profit margins (22.2%) are higher than last year (19.1%).


Past Earnings Growth Analysis

Earnings Trend: PFE's earnings have declined by 2.9% per year over the past 5 years.

Accelerating Growth: PFE's earnings growth over the past year (86.3%) exceeds its 5-year average (-2.9% per year).

Earnings vs Industry: PFE earnings growth over the past year (86.3%) exceeded the Pharmaceuticals industry 17.5%.


Return on Equity

High ROE: PFE's Return on Equity (17.6%) is considered low.


Financial Health

How is Pfizer's financial position?


Financial Position Analysis

Short Term Liabilities: PFE's short term assets ($48.8B) exceed its short term liabilities ($35.7B).

Long Term Liabilities: PFE's short term assets ($48.8B) do not cover its long term liabilities ($63.9B).


Debt to Equity History and Analysis

Debt Level: PFE's debt to equity ratio (55.8%) is considered high.

Reducing Debt: PFE's debt to equity ratio has reduced from 70% to 55.8% over the past 5 years.

Debt Coverage: PFE's debt is well covered by operating cash flow (60%).

Interest Coverage: PFE's interest payments on its debt are well covered by EBIT (14.7x coverage).


Balance Sheet


Dividend

What is Pfizer current dividend yield, its reliability and sustainability?

3.55%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: PFE's dividend (3.55%) is higher than the bottom 25% of dividend payers in the US market (1.33%).

High Dividend: PFE's dividend (3.55%) is low compared to the top 25% of dividend payers in the US market (3.6%).


Stability and Growth of Payments

Stable Dividend: PFE's dividends per share have been stable in the past 10 years.

Growing Dividend: PFE's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (69.7%), PFE's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: PFE's dividends in 3 years are forecast to be well covered by earnings (50% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Albert Bourla (59 yo)

2.67yrs

Tenure

US$21,033,570

Compensation

Dr. Albert Bourla, DVM, Ph.D. serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 and has been its Executive Director since February 23, 2018. Dr. Bourla was Chief Operating Officer...


CEO Compensation Analysis

Compensation vs Market: Albert's total compensation ($USD21.03M) is above average for companies of similar size in the US market ($USD11.36M).

Compensation vs Earnings: Albert's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: PFE's management team is considered experienced (2.7 years average tenure).


Board Members

Experienced Board: PFE's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PFE insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Pfizer Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Pfizer Inc.
  • Ticker: PFE
  • Exchange: NYSE
  • Founded: 1849
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$246.078b
  • Shares outstanding: 5.61b
  • Website: https://www.pfizer.com

Number of Employees


Location

  • Pfizer Inc.
  • 235 East 42nd Street
  • New York
  • New York
  • 10017
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 22:03
End of Day Share Price2021/09/17 00:00
Earnings2021/07/04
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.